Your session is about to expire
← Back to Search
NKTR-255 + CAR-T Cell Therapy for Large B-cell Lymphoma
This trial is testing the combination of NKTR-255 and CAR-T cell therapy to treat patients with large B-cell lymphoma that has relapsed or is refractory.
- Diffuse Large B Cell Lymphoma (DLBCL)
- Large B-Cell Lymphoma
- B-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a Location
Who is running the clinical trial?
- If you have received a stem cell transplant and are currently being treated for graft versus host disease, you cannot participate if it has been less than 30 days since your last treatment.You are able to perform daily activities with at least 60% of your normal ability.You have received CAR-T cell therapy targeting CD19 in the past.You have received a solid organ transplant in the past.You have received treatment with IL-2 or IL-15 medications or similar drugs before.
- Group 1: Treatment (lymphodepletion, liso-cel, NKTR-255)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA given clearance for Polymer-conjugated IL-15 Receptor Agonist NKTR-255?
"Since this is an early-stage trial, the safety of Polymer-conjugated IL-15 Receptor Agonist NKTR-255 has been assessed as a 1 on our scale at Power due to scant evidence regarding its efficacy and protection."
How many individuals have been accepted to participate in this experiment?
"Affirmative, the clinicaltrial.gov portal supports that this trial is soliciting patients at present date. The study was initially made public on December 28th 2022 and revised lastly on November 28th 2022. 24 individuals are targeted for recruitment from a single site."
Are there available slots for participants in this research program?
"Indeed, the data on clinicaltrials.gov confirms that this scientific trial is still recruiting participants. The posting was first uploaded to the website in December 28th 2022 and underwent its last update on November 28th 2022. 24 individuals across 1 site are needed for successful completion of this research endeavour."
What is the aim of this research endeavor?
"According to Nektar Therapeutics, the primary outcome of this clinical trial will be ascertained over a 12-month period following CAR-T cell infusion. This efficacy evaluable population will have its complete response (CR) rate and overall response (OR) rates measured with Kaplan-Meier analysis, in addition to secondary outcomes such as duration of response which is estimated through censoring events or last contact/follow up visits. The safety population's overall survival (OS) is also analyzed using KM method for assessment."
Share this study with friends